Developer docs
API playgroundTry for free, no card

Search company profiles

Radiomics

Full company profile

uuid0009xrf

Namestring
Radiomics
Legal namestring
Radiomics.bio
Websiteurl
radiomics.bio
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Radiomics (legally Radiomics.bio, headquartered in Liège, Belgium) is an AI-powered clinical research organization founded in 2016 that applies deep learning, machine learning, and federated learning to extract quantitative imaging biomarkers from standard-of-care medical images (CT, PET, MRI) for oncology drug development. The company was established by the researchers who coined the term "radiomics" and published seminal work in Nature, and today serves biotech and pharmaceutical companies across all stages of clinical development, from early-phase mechanism-of-action studies through late-phase outcome prediction. Its core technical asset is the proprietary Ikonics® platform, a fully integrated image management system that handles data acquisition, AI-driven segmentation, manual review workflows, feature quantification, and full auditability for regulatory-grade clinical trial imaging.

Radiomics offers five clinical research services bundled around Ikonics: Disease Characterization, Response Evaluation, Response Characterization, Outcome Prediction, and Central Imaging Services (including RECIST/PERCIST/RANO assessments). Its go-to-market is exclusively B2B enterprise sales targeting pharma and biotech clinical development teams, supplemented by active participation at major oncology conferences (ESMO, SITC, ASCO). Revenue is generated through project-based professional services contracts and Software as a Medical Device (SaMD) licensing, with pricing negotiated directly based on trial scope and complexity. Named customers include AstraZeneca (LECOMTE study on ILD/pneumonitis prediction), iOnctura, InhaTarget, DeuterOncology, and academic centers such as Jewish General Hospital/McGill.

The company operates from an 800m² headquarters at LégiaPark in Liège (since September 2022) and a wholly-owned North American subsidiary in Toronto (established 2022), with primary investor Noshaq Group (Belgian institutional investor). Radiomics holds ISO 13485 certification (since January 2022) for SaMD design and development, ISO 27001 certification (since January 2023) for information security, and is GDPR-compliant. The board was reconstituted in February 2025 with Dr. Jan Groen as Chairman, reflecting preparation for a scale-up phase anchored on partnerships with top-tier pharma clients.

Short descriptiontext

Radiomics is an AI-powered clinical research organization that applies deep learning and radiomics to medical imaging analysis, supporting biotech and pharma companies in oncology drug development through its Ikonics platform and clinical trial imaging services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLiège, Belgium
HQ citystring
Liège
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging analysis, clinical trial imaging services, radiomics software platform, oncology drug development, AI imaging biomarkers
Industry3 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
Product category
Medical Imaging Software & Clinical Trial Imaging Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Clinical Research Imaging Services
TypeProfessional Services
Description

Radiomics.bio provides advanced image analysis services to biotech and pharma companies for clinical trials. Services include disease characterization, response evaluation, response characterization, outcome prediction, and central imaging services. Revenue is generated through project-based contracts for clinical trial support across all phases of drug development.

radiomics.bio
2Software as a Medical Device (SaMD)
TypeLicensing Royalties
Description

The company develops software for medical devices used for diagnosis, prognosis, or prediction of disease progression assessed through routine clinical imaging, compliant with ISO 13485 standards.

radiomics.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Ikonics
Description

AI-powered fully integrated image management platform that streamlines image collection and centralizes image quality assessment for enhanced efficiency in radiomic analysis.

radiomics.bio
Core offering1 text field

Radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organization that sells clinical trial imaging analysis services and proprietary Software as a Medical Device (SaMD) to pharmaceutical and biotech companies. Its core technology, the Ikonics® platform, extracts quantitative radiomic biomarkers from standard-of-care CT, PET, and MRI images to quantify treatment response, validate drug mechanisms of action, and predict clinical outcomes across all phases of oncology drug development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Delta-radiomics signature identified patients with clinical benefit at 6 months with AUC of 0.8 (95% CI: 0.65-0.95) on external test dataset
+3 more records
Product overview1 text field

Radiomics is an AI-powered medical imaging clinical research organization offering a unified portfolio consisting of its proprietary Ikonics® platform plus clinical research services. The Ikonics® platform is a fully integrated image management platform that streamlines image collection, centralizes image quality assessment, and enables radiomic feature quantification. This core technology platform is combined with five clinical service offerings: Disease Characterization, Response Evaluation, Response Characterization, Outcome Prediction, and Central Imaging Services. Together, these enable biotech and pharma companies to extract quantitative imaging biomarkers from medical images for insight-based decision making across all phases of clinical drug development.

Product and service6 records
1Ikonics Platform
CategoryCore Software Platform (Software as a Medical Device)
Description

Fully integrated proprietary image management platform that streamlines image collection, centralizes image quality assessment, and manages the radiomics pipeline from data acquisition to imaging feature quantification. Includes secure storage linked to sFTP, AI image segmentation models, manual review workflows, real-time results, and full traceability and auditability. Used by biotech and pharma companies as the core technology layer for clinical trial imaging analysis.

2Disease Characterization Services
CategoryClinical Research Service
Description

Service that characterizes disease using volumetric analysis and radiomic imaging features to enhance understanding of disease at patient, organ, or lesion level for insightful and cost-effective clinical trial designs. Targeted at biotech and pharma sponsors.

3Response Evaluation Services
CategoryClinical Research Service
Description

Service that quantifies treatment response by measuring biological response and validating mechanisms of action through evaluation of phenotypic and anatomical changes of lesions in response to treatment, per arm, per dose, per indication. Enables objective decisions based on drug success potential for each phase of clinical development.

4Response Characterization Services
CategoryClinical Research Service
Description

Service that characterizes biological response to explore and validate drug mechanisms of action by fully quantifying the effect of therapeutics in selected organs or through total tumor burden analysis.

5Outcome Prediction Services
CategoryClinical Research Service
Description

Service that predicts disease progression, treatment response, and clinical outcomes using imaging and clinical data to obtain early insights during clinical trials for decision-making, including identification of responders vs non-responders and adverse event risk such as ILD/pneumonitis.

6Central Imaging Services
CategoryClinical Research Service
Description

Expert central imaging lab services including image protocol optimization, centralized storage, centralized imaging review, and standard assessment methodologies such as RECIST suite, PERCIST, and RANO assessment, conducted in compliance with regulatory and privacy requirements.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-16
Description

AstraZeneca commissioned radiomics.bio to develop AI models capable of detecting and predicting interstitial lung disease/pneumonitis risk in cancer patients. The LECOMTE study uses past clinical trial data and Real-World Evidence combined with radiomic imaging data. Promising results were presented at ESMO 2024 showing the model could successfully identify symptomatic pneumonitis in NSCLC patients treated with AstraZeneca immunotherapy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-05
Description

Digital health pilot project 'Digital Health to Advance and Support Precision Oncology' supported by $358,825 grant from Quebec MEIE. Project integrates medical images, pathology, molecular and clinical data for precision medicine in cancer care, aiming to accelerate patient access to new treatments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-09-05
Description

National Centre of Excellence in Personalized Medicine partnership for the pilot project at Jewish General Hospital, contributing to the PMT (Personalize My Treatment) patient registry with multi-modal data integration.

4OROT - CIUSSS West-Central Montreal
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-09-05
Description

Connected health innovation hub of CIUSSS West-Central Montreal participating in the precision oncology pilot project.

radiomics.bio
5TransMedTech Institute
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-09-05
Description

Contributed $75,000 to the precision oncology pilot project as part of the MEDTEQ+ IMPACT program.

radiomics.bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-04-07
Description

Collaboration awarded 478,000 EUR SPW Win4Company grant for development and validation of AI-based CT imaging biomarker as companion diagnostic for DO-2, a deuterated MET kinase inhibitor. Project combines DeuterOncology's cancer research expertise with Radiomics' advanced AI image analysis to identify lung cancer patients with MET gene alterations.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-11-14
Description

Collaboration on B4PF initiative for early diagnosis of interstitial lung disease/pulmonary fibrosis (ILD/PF). Three Lakes Foundation brings together academia, clinicians and industry to identify imaging insights for early detection, with Radiomics providing radiomic expertise.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Imaging CRO that provides AI-powered imaging biomarkers and central imaging services for oncology clinical trials. Directly comparable to Radiomics' business model of combining AI imaging analytics with pharma/biotech trial services, though larger and publicly listed.

2IXICO
TypeDirect peer
Description

UK-based imaging CRO providing AI-enabled biomarker analysis and central reading services for neuroscience and oncology clinical trials. Highly comparable in serving pharma/biotech with quantitative imaging endpoints and validated image-analysis workflows.

TypeDirect peer
Description

AI-for-drug-discovery platform that partners with pharma to deploy AI on multimodal clinical and imaging data for trial optimization and biomarker discovery. Directly comparable B2B AI-pharma model with imaging and multi-modal analytics components.

4Aignostics
TypeDirect peer
Description

Berlin-based AI pathology/imaging company building foundation models for pharma R&D and clinical trials, with a comparable B2B AI biomarker model. Direct overlap in serving pharma/biotech sponsors with AI-derived imaging biomarkers.

TypeDirect peer
Description

Specialist imaging CRO offering quantitative imaging biomarker services for clinical trials across therapeutic areas. Closely matches Radiomics' positioning as an expert imaging partner for pharma/biotech trial sponsors.

TypeEmerging player
Description

AI medical imaging company developing quantitative imaging biomarkers, primarily in metabolic and fibrotic disease, for pharma R&D and clinical practice. Adjacent competitor with overlapping biomarker-discovery model but different therapeutic focus.

TypeEmerging player
Description

AI medical imaging company with FDA-cleared oncology and chest imaging AI products and pharma/biopharma partnerships. Comparable in applying deep learning to medical imaging but with broader diagnostic-product commercialization.

TypeEmerging player
Description

AI medical imaging company offering comprehensive radiology AI solutions across multiple modalities and clinical workflows. Adjacent competitor in AI medical imaging but focused on diagnostic clinical use rather than pharma trial services.

TypeBroad incumbent
Description

Global medical imaging OEM with embedded AI imaging capabilities sold to hospitals and indirectly used in pharma trials. Larger incumbent with overlapping AI imaging capability but as part of a much broader portfolio rather than a focused radiomics niche.

TypeBroad incumbent
Description

Major medical imaging OEM with AI-enabled imaging platforms and pharma-services adjacencies (e.g., MIM Software). Broad incumbent providing AI imaging infrastructure that competes indirectly with specialist radiomics CROs for pharma spend.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Radiomics

Medical Imaging Software & Clinical Trial Imaging Servicesradiomics.bio

Radiomics is an AI-powered clinical research organization that applies deep learning and radiomics to medical imaging analysis, supporting biotech and pharma companies in oncology drug development through its Ikonics platform and clinical trial imaging services.

What Radiomics does

Radiomics (legally Radiomics.bio, headquartered in Liège, Belgium) is an AI-powered clinical research organization founded in 2016 that applies deep learning, machine learning, and federated learning to extract quantitative imaging biomarkers from standard-of-care medical images (CT, PET, MRI) for oncology drug development. The company was established by the researchers who coined the term "radiomics" and published seminal work in Nature, and today serves biotech and pharmaceutical companies across all stages of clinical development, from early-phase mechanism-of-action studies through late-phase outcome prediction. Its core technical asset is the proprietary Ikonics® platform, a fully integrated image management system that handles data acquisition, AI-driven segmentation, manual review workflows, feature quantification, and full auditability for regulatory-grade clinical trial imaging.

Radiomics offers five clinical research services bundled around Ikonics: Disease Characterization, Response Evaluation, Response Characterization, Outcome Prediction, and Central Imaging Services (including RECIST/PERCIST/RANO assessments). Its go-to-market is exclusively B2B enterprise sales targeting pharma and biotech clinical development teams, supplemented by active participation at major oncology conferences (ESMO, SITC, ASCO). Revenue is generated through project-based professional services contracts and Software as a Medical Device (SaMD) licensing, with pricing negotiated directly based on trial scope and complexity. Named customers include AstraZeneca (LECOMTE study on ILD/pneumonitis prediction), iOnctura, InhaTarget, DeuterOncology, and academic centers such as Jewish General Hospital/McGill.

The company operates from an 800m² headquarters at LégiaPark in Liège (since September 2022) and a wholly-owned North American subsidiary in Toronto (established 2022), with primary investor Noshaq Group (Belgian institutional investor). Radiomics holds ISO 13485 certification (since January 2022) for SaMD design and development, ISO 27001 certification (since January 2023) for information security, and is GDPR-compliant. The board was reconstituted in February 2025 with Dr. Jan Groen as Chairman, reflecting preparation for a scale-up phase anchored on partnerships with top-tier pharma clients.

Radiomics firmographics

Firmographics
Name
Radiomics
Legal name
Radiomics.bio
Website
https://radiomics.bio
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Radiomics is an AI-powered clinical research organization that applies deep learning and radiomics to medical imaging analysis, supporting biotech and pharma companies in oncology drug development through its Ikonics platform and clinical trial imaging services.
Ownership category
akta.pro rank

Radiomics industry classification

Industry
Product category
Medical Imaging Software & Clinical Trial Imaging Services
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Medical imaging analysis
  • Clinical trial imaging services
  • Radiomics software platform
  • Oncology drug development
  • AI imaging biomarkers

Where Radiomics is headquartered

Location

Headquarters

HQ city
Liège
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

Radiomics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Clinical Research Imaging Services: Radiomics.bio provides advanced image analysis services to biotech and pharma companies for clinical trials. Services include disease characterization, response evaluation, response characterization, outcome prediction, and central imaging services. Revenue is generated through project-based contracts for clinical trial support across all phases of drug development.
  2. Software as a Medical Device (SaMD): The company develops software for medical devices used for diagnosis, prognosis, or prediction of disease progression assessed through routine clinical imaging, compliant with ISO 13485 standards.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Radiomics product offering

Product offering

Core offering

Radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organization that sells clinical trial imaging analysis services and proprietary Software as a Medical Device (SaMD) to pharmaceutical and biotech companies. Its core technology, the Ikonics® platform, extracts quantitative radiomic biomarkers from standard-of-care CT, PET, and MRI images to quantify treatment response, validate drug mechanisms of action, and predict clinical outcomes across all phases of oncology drug development.

Product overview

Radiomics is an AI-powered medical imaging clinical research organization offering a unified portfolio consisting of its proprietary Ikonics® platform plus clinical research services. The Ikonics® platform is a fully integrated image management platform that streamlines image collection, centralizes image quality assessment, and enables radiomic feature quantification. This core technology platform is combined with five clinical service offerings: Disease Characterization, Response Evaluation, Response Characterization, Outcome Prediction, and Central Imaging Services. Together, these enable biotech and pharma companies to extract quantitative imaging biomarkers from medical images for insight-based decision making across all phases of clinical drug development.

Differentiator

Problem solved

Functional benefit

Brands

  • Ikonics: AI-powered fully integrated image management platform that streamlines image collection and centralizes image quality assessment for enhanced efficiency in radiomic analysis.

Products and services

  • Ikonics Platform Fully integrated proprietary image management platform that streamlines image collection, centralizes image quality assessment, and manages the radiomics pipeline from data acquisition to imaging feature quantification. Includes secure storage linked to sFTP, AI image segmentation models, manual review workflows, real-time results, and full traceability and auditability. Used by biotech and pharma companies as the core technology layer for clinical trial imaging analysis.
  • Disease Characterization Services Service that characterizes disease using volumetric analysis and radiomic imaging features to enhance understanding of disease at patient, organ, or lesion level for insightful and cost-effective clinical trial designs. Targeted at biotech and pharma sponsors.
  • Response Evaluation Services Service that quantifies treatment response by measuring biological response and validating mechanisms of action through evaluation of phenotypic and anatomical changes of lesions in response to treatment, per arm, per dose, per indication. Enables objective decisions based on drug success potential for each phase of clinical development.
  • Response Characterization Services Service that characterizes biological response to explore and validate drug mechanisms of action by fully quantifying the effect of therapeutics in selected organs or through total tumor burden analysis.
  • Outcome Prediction Services Service that predicts disease progression, treatment response, and clinical outcomes using imaging and clinical data to obtain early insights during clinical trials for decision-making, including identification of responders vs non-responders and adverse event risk such as ILD/pneumonitis.
  • Central Imaging Services Expert central imaging lab services including image protocol optimization, centralized storage, centralized imaging review, and standard assessment methodologies such as RECIST suite, PERCIST, and RANO assessment, conducted in compliance with regulatory and privacy requirements.

Quantifiable outcome

  • Delta-radiomics signature identified patients with clinical benefit at 6 months with AUC of 0.8 (95% CI: 0.65-0.95) on external test dataset
  • +3 more outcomes

Companies that use Radiomics

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Radiomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Radiomics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • AstraZenecacoreStrategic or Co-development Partner · 16 October 2025AstraZeneca commissioned radiomics.bio to develop AI models capable of detecting and predicting interstitial lung disease/pneumonitis risk in cancer patients. The LECOMTE study uses past clinical trial data and Real-World Evidence combined with radiomic imaging data. Promising results were presented at ESMO 2024 showing the model could successfully identify symptomatic pneumonitis in NSCLC patients treated with AstraZeneca immunotherapy.
  • Jewish General Hospital / McGill Centre for Translational Research in CancercoreStrategic or Co-development Partner · 5 September 2023Digital health pilot project 'Digital Health to Advance and Support Precision Oncology' supported by $358,825 grant from Quebec MEIE. Project integrates medical images, pathology, molecular and clinical data for precision medicine in cancer care, aiming to accelerate patient access to new treatments.
  • Exactis InnovationcoreStrategic or Co-development Partner · 5 September 2023National Centre of Excellence in Personalized Medicine partnership for the pilot project at Jewish General Hospital, contributing to the PMT (Personalize My Treatment) patient registry with multi-modal data integration.
  • OROT - CIUSSS West-Central MontrealminorStrategic or Co-development Partner · 5 September 2023Connected health innovation hub of CIUSSS West-Central Montreal participating in the precision oncology pilot project.
  • TransMedTech InstituteminorStrategic or Co-development Partner · 5 September 2023Contributed $75,000 to the precision oncology pilot project as part of the MEDTEQ+ IMPACT program.
  • DeuterOncologycoreStrategic or Co-development Partner · 7 April 2023Collaboration awarded 478,000 EUR SPW Win4Company grant for development and validation of AI-based CT imaging biomarker as companion diagnostic for DO-2, a deuterated MET kinase inhibitor. Project combines DeuterOncology's cancer research expertise with Radiomics' advanced AI image analysis to identify lung cancer patients with MET gene alterations.
  • Three Lakes FoundationminorStrategic or Co-development Partner · 14 November 2022Collaboration on B4PF initiative for early diagnosis of interstitial lung disease/pulmonary fibrosis (ILD/PF). Three Lakes Foundation brings together academia, clinicians and industry to identify imaging insights for early detection, with Radiomics providing radiomic expertise.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Radiomics competitors and assessment

Company assessment

Direct peers

  • Median Technologies: Imaging CRO that provides AI-powered imaging biomarkers and central imaging services for oncology clinical trials. Directly comparable to Radiomics' business model of combining AI imaging analytics with pharma/biotech trial services, though larger and publicly listed.
  • IXICO: UK-based imaging CRO providing AI-enabled biomarker analysis and central reading services for neuroscience and oncology clinical trials. Highly comparable in serving pharma/biotech with quantitative imaging endpoints and validated image-analysis workflows.
  • Owkin: AI-for-drug-discovery platform that partners with pharma to deploy AI on multimodal clinical and imaging data for trial optimization and biomarker discovery. Directly comparable B2B AI-pharma model with imaging and multi-modal analytics components.
  • Aignostics: Berlin-based AI pathology/imaging company building foundation models for pharma R&D and clinical trials, with a comparable B2B AI biomarker model. Direct overlap in serving pharma/biotech sponsors with AI-derived imaging biomarkers.
  • Image Analysis Group (IAG): Specialist imaging CRO offering quantitative imaging biomarker services for clinical trials across therapeutic areas. Closely matches Radiomics' positioning as an expert imaging partner for pharma/biotech trial sponsors.

Emerging players

  • Perspectum: AI medical imaging company developing quantitative imaging biomarkers, primarily in metabolic and fibrotic disease, for pharma R&D and clinical practice. Adjacent competitor with overlapping biomarker-discovery model but different therapeutic focus.
  • Lunit: AI medical imaging company with FDA-cleared oncology and chest imaging AI products and pharma/biopharma partnerships. Comparable in applying deep learning to medical imaging but with broader diagnostic-product commercialization.
  • Annalise.ai: AI medical imaging company offering comprehensive radiology AI solutions across multiple modalities and clinical workflows. Adjacent competitor in AI medical imaging but focused on diagnostic clinical use rather than pharma trial services.

Broad incumbents

  • Philips (IntelliSpace AI): Global medical imaging OEM with embedded AI imaging capabilities sold to hospitals and indirectly used in pharma trials. Larger incumbent with overlapping AI imaging capability but as part of a much broader portfolio rather than a focused radiomics niche.
  • GE HealthCare (Edison AI): Major medical imaging OEM with AI-enabled imaging platforms and pharma-services adjacencies (e.g., MIM Software). Broad incumbent providing AI imaging infrastructure that competes indirectly with specialist radiomics CROs for pharma spend.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Radiomics social profiles

Digital presence

Radiomics compliance and trust

Trust signal

Compliance3 records

Radiomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Radiomics leadership team

Management profile

Number of profiles

Profiles7 records

Radiomics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Radiomics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Radiomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Radiomics

What does Radiomics do?

Radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organization that sells clinical trial imaging analysis services and proprietary Software as a Medical Device (SaMD) to pharmaceutical and biotech companies. Its core technology, the Ikonics® platform, extracts quantitative radiomic biomarkers from standard-of-care CT, PET, and MRI images to quantify treatment response, validate drug mechanisms of action, and predict clinical outcomes across all phases of oncology drug development.

Is Radiomics a public or private company?

Radiomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Radiomics founded?

Radiomics was founded in 2016. It employs 11 to 50 people.

Where is Radiomics based?

Radiomics is headquartered in Liège, Belgium, in the Europe region.

How does Radiomics make money?

Two revenue lines are on record. Clinical Research Imaging Services are the primary driver. The others are software as a Medical Device (SaMD).

Who are Radiomics's main competitors?

Direct peers on record are Median Technologies, IXICO, Owkin, Aignostics and Image Analysis Group (IAG). Emerging players are Perspectum, Lunit and Annalise.ai. Broad incumbents are Philips (IntelliSpace AI) and GE HealthCare (Edison AI).

Does Radiomics have an API?

No public API is recorded for Radiomics.

What industry is Radiomics in?

Radiomics's product category is Medical Imaging Software & Clinical Trial Imaging Services. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLACANAF, SaMD – Digital Biomarkers & Algorithmic Endpoints. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartupSeekerradiomics.bio - Funding: $10M+Radiomics.bio has raised $10 million+ in funding to support its AI-powered clinical image analysis platform focused on oncology. The company's technology utilizes radiomics and deep learning to extract quantitative data from medical images, aiming to enhance diagnostic accuracy and treatment personalization for healthcare professionals and pharmaceutical partners.Radiomicsradiomics.bioradiomics.bio is an AI-powered clinical research organization that optimizes oncology treatment development through its integrated Ikonics® platform. The company supports biotech and pharma partners by quantifying treatment response and developing predictive tools for decision-making during clinical trials.Tracxn2025 Company Profile, Funding, Competitors & FinancialsRadiomics, a company founded in 2016 and headquartered in Liege, Belgium, secured its latest funding through a $217K grant from the European Union on January 1, 2023. The company employs 28 people as of late 2022 and ranks third among 44 active competitors in its sector. Its primary competitors identified include Perceptive Asterand Bioscience and Pulse Medical Imaging Technology.BreakingcancernewsFrom Pixels to Precision: “Radiomics” Transforms Cancer CareRadiomics.bio, a company specializing in advanced imaging analysis for the pharmaceutical and biotech industries, is leveraging artificial intelligence to extract quantitative data from medical scans for cancer research. This radiomics approach aims to provide more precise insights into tumor biology and treatment responses compared to traditional RECIST v1.1 criteria, particularly in the context of immunotherapy clinical trials. The technology facilitates personalized cancer care by enabling non-invasive diagnosis and real-time monitoring of disease progression.ReviewedCan Only the Shape Feature in Radiomics Help Machine Learning Show That Bladder Cancer Has Invaded Muscles?The study evaluates the diagnostic performance of radiomic shape features in predicting muscle-invasive bladder cancer (BCa) using MRI images, with a retrospective cohort of 60 patients. The results show that shape features from ADC maps achieve up to 83.3% accuracy, suggesting potential for non-invasive invasion assessment.GlobeNewswirePaving the way for better diagnosis, treatment and care inThree Lakes Foundation expanded B4PF, an initiative for early diagnosis and therapeutic development of ILD/PF, partnering with Weill Cornell Medicine, Vanderbilt University Medical Center, and Radiomics. The project aims to use CT imaging to identify early signs of pulmonary fibrosis in relatives and individuals with incidental abnormalities. It targets over five million global PF patients and 50,000 U.S. IPF diagnoses annually.RadiomicsRadiomics is officially ISO 13485 certifiedRadiomics has received ISO 13485:2016 certification for its Quality Management System from the notified body IMQ, validating its compliance with medical device regulatory standards. This certification covers the design and development of its Software as a Medical Device used for disease diagnosis and prognosis through clinical imaging. The achievement positions Radiomics as a trustworthy partner for research collaborations and clients in the pharmaceutical and biotech sectors.PR NewswireKazia Enrols First Patient to EVT801 Phase I Clinical TrialKazia Therapeutics has commenced enrollment for a Phase I clinical trial of EVT801, an investigational VEGFR3 inhibitor for cancer therapy licensed from Evotec SE in April 2021. The trial will enroll up to 60 patients to assess safety, tolerability, pharmacokinetics, and preliminary efficacy signals, with a second expansion stage focused on renal cell carcinoma and soft-tissue sarcoma patients. The study is being conducted at IUCT-Oncopole in Toulouse, France, with Evotec supporting biomarker analyses and Radiomics providing AI-based imaging analysis.